KGI’s fellowship program is the gateway for PharmD and PhD graduates to experience and explore the biopharmaceutical industry’s diverse working environment.
Download the Fellowship Brochure
KGI and Abbott Pharmaceuticals are proud to announce a 24-month fellowship. The Abbott U.S. Medical Affairs Fellowship is a two-year post-doctoral program which allows a PharmD graduate or PhD to gain in-depth experience in diabetes technology and operations within Medical Affairs. Through cross-functional collaboration with field-based medical colleagues and Medical Affairs leadership, the fellow will gain experience in medical communication; medical information including the creation of Medical Information Standardized letters; global publication process; development of patient and professional educational resources; medical reviews; fostering diabetes advocacy among healthcare professionals; scientific congress planning, attendance, and staffing support of medical information booths; medical review of promotional material; and health economics and outcomes research. In addition, the fellow will participate in product development teams, contributing clinical and user experience insights. The fellow will be integrated into the medical science liaison team as a critical member of the team where the fellow will have the opportunity to lead key educational initiatives.
KGI and AbbVie are KGI are proud to announce a 24-month fellowship with AbbVie. Pharmacyclics is a wholly-owned subsidiary of AbbVie (NYSE:ABBV), a global, research-based biopharmaceutical company. More than 1,200 Pharmacyclics and AbbVie research scientists, clinicians, marketing, operations and corporate professionals work in the San Francisco Bay Area.
The fellowship will provide comprehensive practical hands-on biopharmaceutical training and foster an environment of learning with a leading biopharmaceutical company. The fellow will be paired with leaders in different medical affairs functional areas. The collaborative environment will offer the fellow an enduring network and exposure to grow exceptional skills.
KGI and Ascendis Pharma are proud to announce a 24-month fellowship with Ascendis. The GCP & PV Regulatory Compliance Fellowship provides comprehensive practical hands-on biopharmaceutical training and fosters an environment of learning within a fast-growing biopharmaceutical company. The fellow will be paired with leaders in the GCP & PV Regulatory Compliance functional area and will have the opportunity to support various clinical trial and study teams and to work cross-functionally with all departments. The collaborative environment will offer the fellow an enduring network and exposure to all aspects of the drug development process.
KGI and Ascendis Pharma are proud to announce a 24-month fellowship with Ascendis designed to provide pharmacists with broad exposure to global medical affairs-scientific affairs. At Ascendis, we are passionate about patients and science. Our growing development pipeline of innovative new therapies is driven by the flexibility of our TransCon technologies. We have multiple prodrug therapies in development, across two therapeutic areas—endocrinology and oncology. The above Fellowship provides an opportunity to learn broad skills that are necessary to excel within medical Affairs. The position will be based in Palo Alto or Princeton and the Fellow is expected to collaborate with various members of the Ascendis Medical Affairs and Scientific Affairs team on diverse projects.
KGI and Edwards Lifesciences are proud to announce a 24-month fellowship with the Edwards Lifesciences Transcatheter Mitral and Tricuspid Therapies (TMTT) division. TMTT is passionate about developing breakthrough solutions for patients suffering from structural heart disease. The Scientific Communications Fellowship is a unique opportunity to play a role in the growth of new cutting-edge transcatheter mitral and tricuspid heart valve therapies. This fellowship is designed to provide you with an exciting opportunity to learn broad skills required for the planning and implementation of scientific communications of clinical trials across a portfolio of mitral valve therapies and executing abstracts, presentations, and manuscripts. The position will be based in Edwards Lifesciences’ beautiful Irvine campus. Come join our trailblazing culture!
KGI and Edwards Lifesciences are proud to announce a 24-month fellowship with the Edwards Lifesciences Transcatheter Mitral and Tricuspid Therapies (TMTT) division. TMTT is passionate about developing breakthrough solutions for patients suffering from structural heart disease. The Clinical Science Fellowship is a unique opportunity to play a role in developing new cutting-edge transcatheter mitral and tricuspid heart valve therapies. The fellowship is designed to provide pharmacists with broad exposure to clinical science within the field of structural heart disease therapies, including medical writing and clinical trial design. This is also an opportunity for the Fellow to learn about the life cycle of regulated devices, product development processes, and global regulatory approval pathways.
The in vitro diagnostics (IVD) fellowship aims to develop next generation leaders in the diagnostics industry.
The two-year fellowship program will provide a deep understanding on the development of new diagnostic assays and regulatory submissions. The fellowship will support the development of QuidelOrthoTM proprietary IVD assays in all phases from preparing the product requirements document to product launch. The fellow will get an opportunity to engage in different projects and learn about various steps wherein this approach, the fellow will simultaneously learn all the stages of assay development. Fellows will impart key industrial skills like critical thinking, decision making, scientific communication, presentation, risk management and the ability to adapt and thrive in a multicultural environment. Eventually, at the end of this program, the fellow will be able to lead a team for developing next generation IVD assays and
make an impact on patients’ lives.